A gastrointestinal stromal tumor (GIST) is a rare type of non-epithelial tumor that originates in the gastrointestinal (GI) tract. These tumors most commonly develop in the stomach or the small intestine, although they can occur anywhere along the GI tract, from the esophagus to the rectum.
The main treatment modalities for gastrointestinal stromal tumors include chemotherapy, targeted therapy, and others. Chemotherapy is a medical treatment that utilizes potent drugs to target and eliminate rapidly dividing cells in the body, including cancer cells. It is prescribed for various indications such as those affecting the stomach, small intestine, and other parts of the GI tract. Different end-users, including hospitals, clinics, specialized cancer treatment centers, and others, may administer chemotherapy as part of the treatment regimen.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The gastrointestinal stromal tumor market research report is one of a series of new reports from The Business Research Company that provides gastrointestinal stromal tumor market statistics, including gastrointestinal stromal tumor industry global market size, regional shares, competitors with a gastrointestinal stromal tumor market share, detailed gastrointestinal stromal tumor market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal stromal tumor industry. This gastrointestinal stromal tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The gastrointestinal stromal tumor market size has grown strongly in recent years. It will grow from $1.28 billion in 2024 to $1.36 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increased awareness and early diagnosis, emergence of targeted therapies, enhanced surgical techniques, development of personalized medicine, improvements in supportive care.
The gastrointestinal stromal tumor market size is expected to see strong growth in the next few years. It will grow to $1.82 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to continued research and drug development, rise in patient-centric healthcare, integration of precision medicine in clinical practice, increasing access to targeted therapies, expanding genomic profiling capabilities. Major trends in the forecast period include growing collaboration in research and development, advancements in diagnostic technologies, collaborative research and clinical trials, increased focus on early detection and diagnosis, exploration of combination therapies.
The forecast of 7.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Targeted therapies like imatinib mesylate sourced from Switzerland may see 30% price hikes from tariffs, compromising treatment adherence for this rare cancer and increasing annual patient costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing incidence of stomach cancer is expected to drive the growth of the gastrointestinal stromal tumor market in the future. Stomach cancer is characterized by the uncontrolled proliferation of malignant cells in the stomach lining. While gastrointestinal stromal tumors (GISTs) can develop in the stomach, they are different from stomach cancer. Patients with GISTs have been observed to have a heightened risk of developing other cancers, including small bowel adenocarcinoma, particularly when two distinct tumors collide and merge. For example, the American Cancer Society, a U.S.-based professional organization, projected in January 2024 that approximately 26,890 new cases of stomach cancer and 10,880 deaths will occur in the U.S. in 2024, representing 1.5% of all new cancer diagnoses. Hence, the rising incidence of stomach cancer is propelling the growth of the gastrointestinal stromal tumor market.
The growing demand for precision medicine is anticipated to further advance the gastrointestinal stromal tumor market in the coming years. Precision medicine refers to a tailored approach to medical treatment that customizes healthcare decisions, interventions, and therapies based on individual patient characteristics, such as genetics and lifestyle factors. In the context of gastrointestinal stromal tumors, precision medicine involves molecular profiling to detect specific mutations, which directs targeted therapies like imatinib, enhancing treatment effectiveness while reducing side effects through personalized interventions. For instance, a report by the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, indicated in February 2023 that personalized medicines represented 35% of newly approved new molecular entities (NMEs) in 2021, and with 12 new approvals in 2022, they have consistently accounted for at least a quarter of new drug approvals over the past eight years, marking a significant rise from less than 10% a decade ago. Therefore, the growing demand for precision medicine is driving the expansion of the gastrointestinal stromal tumor market.
Major companies in the gastrointestinal stromal tumor market are developing innovative drugs like QINLOCK (Ripretinib) to cater to larger customer bases, boost sales, and enhance revenue. QINLOCK (Ripretinib) is a prescription medication used for the treatment of advanced gastrointestinal stromal tumors (GIST). For example, in January 2024, the U.S. Food and Drug Administration (FDA), a federal agency, reported that the Center for Drug Evaluation and Research (CDER) approved 37 novel drugs in 2022, which increased to 55 drugs in 2023. CDER noted that 20 of the 55 novel drugs (36%) approved in 2023 were classified as first-in-class.
In June 2022, Immatics N.V., a Germany-based biotechnology company, formed a partnership with Bristol Myers Squibb to develop gamma delta allogeneic cell therapy programs. This collaboration aims to create advanced cancer immunotherapies with the potential to enhance the treatment of various cancers, including gastrointestinal stromal tumors (GISTs). Bristol Myers Squibb, a US-based pharmaceutical company, is actively involved in developing treatments related to GISTs.
Major companies operating in the gastrointestinal stromal tumor market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Advenchen Laboratories LLC, Arog Pharmaceuticals Inc., AB Sciences S.A.
North America was the largest region in the gastrointestinal stromal tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the gastrointestinal stromal tumor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The gastrointestinal stromal tumor market includes revenues earned by entities by providing services such as diagnostic services, pathology services, pathology services, and pathology services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastrointestinal stromal tumor market also includes sales of targeted therapy, chemotherapy, radiation therapy. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gastrointestinal Stromal Tumor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gastrointestinal stromal tumor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gastrointestinal stromal tumor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gastrointestinal stromal tumor market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment Type: Chemotherapy; Targeted Therapy; Other Treatment Types
- 2) By Indication: Stomach; Small Intestine; Others Indications
- 3) By End-User: Hospitals; Clinics; Specialized Cancer Treatment Centers; Other End-Users
- Subsegments:
- 1) By Chemotherapy: Traditional Chemotherapy Agents; Combination Chemotherapy Regimens
- 2) By Targeted Therapy: Tyrosine Kinase Inhibitors; Other Targeted Agents
- 3) By Other Treatment Types: Surgery; Radiation Therapy; Clinical Trials For Novel Therapies
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Bayer AG; Novartis AG; Merck & Co. Inc.; GlaxoSmithKline plc; Bristol-Myers Squibb Company; Sanofi S.A.; AstraZeneca plc; Eli Lilly and Company; Daiichi Sankyo Co. Ltd.; Eisai Co. Ltd.; Sun Pharmaceutical Industries Limited; Jiangsu Hengrui Medicine Co. Ltd.; Exelixis Inc.; NATCO Pharma Ltd.; Blueprint Medicines Corporation; Array BioPharma Inc.; Deciphera Pharmaceuticals Inc.; Ono Pharmaceutical Co. Ltd.; Boston Biomedical Inc.; DNAtrix Inc.; Advenchen Laboratories LLC; Arog Pharmaceuticals Inc.; AB Sciences S.A.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Gastrointestinal Stromal Tumor Market Characteristics
3. Gastrointestinal Stromal Tumor Market Trends And Strategies
4. Gastrointestinal Stromal Tumor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Gastrointestinal Stromal Tumor Growth Analysis And Strategic Analysis Framework
- 5.1. Global Gastrointestinal Stromal Tumor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Gastrointestinal Stromal Tumor Market Growth Rate Analysis
- 5.4. Global Gastrointestinal Stromal Tumor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Gastrointestinal Stromal Tumor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Gastrointestinal Stromal Tumor Total Addressable Market (TAM)
6. Gastrointestinal Stromal Tumor Market Segmentation
- 6.1. Global Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chemotherapy
- Targeted Therapy
- Other Treatment Types
- 6.2. Global Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Stomach
- Small Intestine
- Others Indications
- 6.3. Global Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Specialized Cancer Treatment Centers
- Other End-Users
- 6.4. Global Gastrointestinal Stromal Tumor Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Traditional Chemotherapy Agents
- Combination Chemotherapy Regimens
- 6.5. Global Gastrointestinal Stromal Tumor Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tyrosine Kinase Inhibitors
- Other Targeted Agents
- 6.6. Global Gastrointestinal Stromal Tumor Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Surgery
- Radiation Therapy
- Clinical Trials For Novel Therapies
7. Gastrointestinal Stromal Tumor Market Regional And Country Analysis
- 7.1. Global Gastrointestinal Stromal Tumor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Gastrointestinal Stromal Tumor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Gastrointestinal Stromal Tumor Market
- 8.1. Asia-Pacific Gastrointestinal Stromal Tumor Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Gastrointestinal Stromal Tumor Market
- 9.1. China Gastrointestinal Stromal Tumor Market Overview
- 9.2. China Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Gastrointestinal Stromal Tumor Market
- 10.1. India Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Gastrointestinal Stromal Tumor Market
- 11.1. Japan Gastrointestinal Stromal Tumor Market Overview
- 11.2. Japan Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Gastrointestinal Stromal Tumor Market
- 12.1. Australia Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Gastrointestinal Stromal Tumor Market
- 13.1. Indonesia Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Gastrointestinal Stromal Tumor Market
- 14.1. South Korea Gastrointestinal Stromal Tumor Market Overview
- 14.2. South Korea Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Gastrointestinal Stromal Tumor Market
- 15.1. Western Europe Gastrointestinal Stromal Tumor Market Overview
- 15.2. Western Europe Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Gastrointestinal Stromal Tumor Market
- 16.1. UK Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Gastrointestinal Stromal Tumor Market
- 17.1. Germany Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Gastrointestinal Stromal Tumor Market
- 18.1. France Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Gastrointestinal Stromal Tumor Market
- 19.1. Italy Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Gastrointestinal Stromal Tumor Market
- 20.1. Spain Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Gastrointestinal Stromal Tumor Market
- 21.1. Eastern Europe Gastrointestinal Stromal Tumor Market Overview
- 21.2. Eastern Europe Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Gastrointestinal Stromal Tumor Market
- 22.1. Russia Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Gastrointestinal Stromal Tumor Market
- 23.1. North America Gastrointestinal Stromal Tumor Market Overview
- 23.2. North America Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Gastrointestinal Stromal Tumor Market
- 24.1. USA Gastrointestinal Stromal Tumor Market Overview
- 24.2. USA Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Gastrointestinal Stromal Tumor Market
- 25.1. Canada Gastrointestinal Stromal Tumor Market Overview
- 25.2. Canada Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Gastrointestinal Stromal Tumor Market
- 26.1. South America Gastrointestinal Stromal Tumor Market Overview
- 26.2. South America Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Gastrointestinal Stromal Tumor Market
- 27.1. Brazil Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Gastrointestinal Stromal Tumor Market
- 28.1. Middle East Gastrointestinal Stromal Tumor Market Overview
- 28.2. Middle East Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Gastrointestinal Stromal Tumor Market
- 29.1. Africa Gastrointestinal Stromal Tumor Market Overview
- 29.2. Africa Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Gastrointestinal Stromal Tumor Market Competitive Landscape And Company Profiles
- 30.1. Gastrointestinal Stromal Tumor Market Competitive Landscape
- 30.2. Gastrointestinal Stromal Tumor Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Gastrointestinal Stromal Tumor Market Other Major And Innovative Companies
- 31.1. GlaxoSmithKline plc
- 31.2. Bristol-Myers Squibb Company
- 31.3. Sanofi S.A.
- 31.4. AstraZeneca plc
- 31.5. Eli Lilly and Company
- 31.6. Daiichi Sankyo Co. Ltd.
- 31.7. Eisai Co. Ltd.
- 31.8. Sun Pharmaceutical Industries Limited
- 31.9. Jiangsu Hengrui Medicine Co. Ltd.
- 31.10. Exelixis Inc.
- 31.11. NATCO Pharma Ltd.
- 31.12. Blueprint Medicines Corporation
- 31.13. Array BioPharma Inc.
- 31.14. Deciphera Pharmaceuticals Inc.
- 31.15. Ono Pharmaceutical Co. Ltd.
32. Global Gastrointestinal Stromal Tumor Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Gastrointestinal Stromal Tumor Market
34. Recent Developments In The Gastrointestinal Stromal Tumor Market
35. Gastrointestinal Stromal Tumor Market High Potential Countries, Segments and Strategies
- 35.1 Gastrointestinal Stromal Tumor Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Gastrointestinal Stromal Tumor Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Gastrointestinal Stromal Tumor Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
